Merck application for RSV treatment Clesrovimab for infants accepted by USFDA Ruchika Sharma19 Dec 2024 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted...
Merck discontinues clinical development programs for vibostolimab, favezelimab Ruchika Sharma18 Dec 2024 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical development programs for...
Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck Ruchika Sharma11 Dec 2024 5:54 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA...
USFDA grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for Metastatic Nonsquamous Non Small Cell Lung Cancer with EGFR Mutations: Merck Ruchika Sharma4 Dec 2024 1:01 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has granted...
Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma Ruchika Sharma19 Nov 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing Ruchika Sharma14 Nov 2024 12:33 PM ISTBoston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of...
Merck acquires cancer therapy developer Modifi Biosciences Ruchika Sharma31 Oct 2024 11:00 AM ISTNew Haven: Modifi Biosciences, Inc., has announced that the company has been acquired by Merck, known as MSD outside of the United States...
MSD Phase 3 trial of head and neck cancer treatment meets primary endpoint Ruchika Sharma13 Oct 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA...
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers Ruchika Sharma24 Sept 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
USFDA nod to Merck KEYTRUDA plus Pemetrexed, Platinum Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma Ruchika Sharma23 Sept 2024 7:26 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) has approved KEYTRUDA,...
Merck, EyeBio announce initiation of Phase 2b/3 clinical trial for Restoret for Diabetic Macular Edema Ruchika Sharma8 Sept 2024 4:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co., Inc., Rahway,...
Merck discontinues Phase 3 trial for lung cancer combo drug Ruchika Sharma11 Aug 2024 10:00 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the Phase 3 KeyVibe-008 trial based on...
